Efgartigimod Market Size, Forecast, and Emerging Insight - 2032

Efgartigimod Market Size, Forecast, and Emerging Insight − 2032

“Efgartigimod Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about Efgartigimod for Inflammatory Myositis (IM) in the seven major markets. A detailed picture of the Efgartigimod for IM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the Efgartigimod for IM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Efgartigimod market forecast analysis for IM in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in IM.

Drug Summary

Efgartigimod, an experimental antibody fragment, is specifically designed to target the neonatal Fc receptor (FcRn) and is considered a pioneering treatment option. It is currently being evaluated for its potential to treat patients suffering from inflammatory myositis, a severe autoimmune disease. These patients have confirmed levels of pathogenic immunoglobulin G (IgG) autoantibodies, and there is a significant lack of effective medical solutions for their condition.

It was previously approved as VYVGART (efgartigimod) in the US, Europe, and Japan for treating generalized myasthenia gravis (gMG) in adult anti-acetylcholine receptor antibody-positive adult patients. Currently, the ALKIVIA trial is on track and is being conducted for three subtypes of idiopathic inflammatory myopathies (myositis), including immune-mediated necrotizing myopathy, anti-synthetase syndrome, and dermatomyositis; interim analysis is planned of first 30 patients of each subtype.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the Efgartigimod description, mechanism of action, dosage and administration, research and development activities in Inflammatory Myositis (IM).

Elaborated details on Efgartigimod regulatory milestones and other development activities have been provided in this report.

The report also highlights the Efgartigimod research and development activities in IM across the United States, Europe, and Japan.

The report also covers the patents information with expiry timeline around Efgartigimod.

The report contains forecasted sales of Efgartigimod for IM till 2032.

Comprehensive coverage of the late-stage emerging therapies for IM.

The report also features the SWOT analysis with analyst views for Efgartigimod in IM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Efgartigimod Analytical Perspective by DelveInsight

In-depth Efgartigimod Market Assessment

This report provides a detailed market assessment of Efgartigimod for Inflammatory Myositis (IM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

Efgartigimod Clinical Assessment

The report provides the clinical trials information of Efgartigimod for Inflammatory Myositis (IM) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Inflammatory Myositis (IM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Efgartigimod dominance.

Other emerging products for IM are expected to give tough market competition to Efgartigimod and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Efgartigimod in IM.

Our in-depth analysis of the forecasted sales data of Efgartigimod from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Efgartigimod in IM.

Key Questions

What is the product type, route of administration and mechanism of action of Efgartigimod?

What is the clinical trial status of the study related to Efgartigimod in Inflammatory Myositis (IM) and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Efgartigimod development?

What are the key designations that have been granted to Efgartigimod for IM?

What is the forecasted market scenario of Efgartigimod for IM?

What are the forecasted sales of Efgartigimod in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?

What are the other emerging products available and how are these giving competition to Efgartigimod for IM?

Which are the late-stage emerging therapies under development for the treatment of IM?